EUCTR2021-003208-42-BE进行中（未招募）1 期
A Phase 3, Open Label, Randomized, Non-Inferiority Pharmacokinetic Study of Nivolumab Subcutaneous (Nivo SC) Versus Intravenous (Nivo IV) Administration in Participants with Stage IIIA/B/C/D or Stage IV Adjuvant Melanoma Following Complete Resection - CheckMate-6GE: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 6GE
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 379
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Not applicable per Protocol Amendment 01 (as of 24-Feb-2023, enrollment in this study has closed).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 276
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 103
排除标准
- •Not applicable per Protocol Amendment 01 (as of 24-Feb-2023, enrollment in this study has closed).
研究者
相似试验
进行中（未招募）
1 期
A Pharmacokinetic Study of Nivolumab Administered Subcutaneously vs Intravenous Nivolumab in Participants with Stage III A/B/C/D or Stage IV Melanoma Following Complete ResectioEUCTR2021-003208-42-PLBristol-Myers Squibb International Corporation379
进行中（未招募）
1 期
A Study of Subcutaneous Nivolumab in Previously Treated Advanced or Metastatic Clear Cell Renal Cell CarcinomaMetastatic Clear Cell Renal Cell CarcinomaMedDRA version: 21.1Level: LLTClassification code 10050076Term: Metastatic renal carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003655-15-PLBristol-Myers Squibb International Corporation495
进行中（未招募）
1 期
A Study of Subcutaneous Nivolumab in Previously Treated Advanced or Metastatic Clear Cell Renal Cell CarcinomaMetastatic Clear Cell Renal Cell CarcinomaMedDRA version: 21.1Level: LLTClassification code 10050076Term: Metastatic renal carcinomaSystem Organ Class: 100000004864EUCTR2020-003655-15-FRBristol-Myers Squibb International Corporation458
招募中
3 期
A Study of Subcutaneous Nivolumab in Previously Treated Advanced or Metastatic Clear Cell Renal Cell Carcinoma2023-503280-42-00Bristol-Myers Squibb Services Unlimited Company134
进行中（未招募）
1 期
A Study of Subcutaneous Nivolumab in Previously Treated Advanced or Metastatic Clear Cell Renal Cell CarcinomaMetastatic Clear Cell Renal Cell CarcinomaMedDRA version: 21.1Level: LLTClassification code 10050076Term: Metastatic renal carcinomaSystem Organ Class: 100000004864EUCTR2020-003655-15-PTBristol-Myers Squibb International Corporation458